More Information on inulin-propionate ester
EU approval of inulin-propionate ester as a new food item:
https://eur-lex.europa.eu/eli/reg_impl/2026/1219/oj
Who makes and controls IPE
The originators and IP holders (Imperial College London + University of Glasgow). IPE was invented by a team led by Professor Gary Frost (Imperial) and Dr Douglas Morrison (University of Glasgow, based at the Scottish Universities Environmental Research Centre, SUERC). They developed inulin-propionate ester to investigate the role of propionate produced by the gut microbiota in human health. The underlying patent is WO2014020344A1 / US9642875B2 (“Compounds and their effects on appetite control and insulin sensitivity”), filed by the University of Glasgow and Imperial Innovations (Imperial’s tech-transfer arm), naming Frost, Morrison, and Tom Preston as inventors. Imperial College London
The spinout company. Across their recent publications, the three inventors disclose that they are founding directors of a Spinout company aimed at commercialising IPE production. Notably, the company is never named in any of the papers I could find — the disclosures consistently refer to it only as “a Spinout company.” So a commercialization vehicle exists, but its trading name isn’t in the public literature. PubMed Central
Who has actually synthesized the material. Historically, essentially all IPE used in studies was made to order in Morrison’s laboratory at SUERC/Glasgow, not bought from a supplier. The synthesis reacts food-grade chicory inulin with propionic anhydride under alkaline conditions, then purifies and spray-dries it. Inulin was used as the carrier (Beneo HP), inorganic reagents from Sigma-Aldrich, and propionic anhydride from Acros Chemicals/Fisher. For the food-product trials, the ingredient was formulated into breads and smoothies by contract labs (Leatherhead Food Research). This is bespoke research-scale manufacture, not a catalogued product. PubMed Central
The EU regulatory route (new, 2025–2026). This is the closest thing to a real commercial channel. On 15 February 2018, Imperial College Hammersmith Campus applied to place inulin-propionate ester on the EU market as a novel food. EFSA judged it safe in 2025, and the EU authorized it. Critically, only Imperial College Hammersmith Campus, the original applicant, may place this novel food on the EU market for the first 5 years unless it grants permission or another applicant obtains separate authorisation, and this novel food may be placed on the EU market from 30 June 2026. Authorized uses and maximum levels are 17 g per 100 g in cereal bars and 3 g per 100 ml in fruit smoothies, labelled as “inulin-propionate ester.” So as of a couple of days ago, Imperial holds a 5-year exclusive right to sell IPE-containing foods in the EU. AgrinfoAgrinfo
Chinese synthesis IP. A separate Chinese patent (CN106957377A) describes a manufacturing method for inulin propionate ester, claiming a process that is simple, low energy, low production cost, high yield, and suitable for preparing high-substitution-degree inulin propionate ester. This indicates process know-how exists in China, but I found no evidence of a Chinese firm selling finished IPE as a catalogued product. Google Patents
What you cannot buy. Amazon, Alibaba, and the bulk nutraceutical suppliers return only plain inulin, not IPE. One trade write-up put it plainly: at time of writing there aren’t any commercially available IPE supplements.
Cost and pricing
There is no public retail or wholesale price for IPE, because there has been no product to price. What can be estimated:
The raw materials are cheap. Bulk chicory inulin runs roughly $7–10 per kg in organic food-grade form, and propionic anhydride is an inexpensive commodity chemical (typically single-digit dollars per kg at industrial scale). The material cost of a 10 g daily dose is therefore trivial — pennies of inputs. Alibaba
The real cost drivers are the specialized esterification, solvent-free purification, spray-drying, quality control (FTIR and GC to confirm ester bonds and propionate loading), and — for anything sold as food — novel-food regulatory compliance. None of these have a published unit cost. If you’re trying to model a price, the honest answer is that it will be set by whatever Imperial’s spinout or its licensees charge once product actually ships, and that figure isn’t public yet. For research quantities, groups have historically obtained it through direct academic collaboration with the Glasgow/Imperial team rather than by purchase.
The scientific and clinical studies
The evidence base is essentially one coordinated research program from the Imperial/Glasgow group, spanning about a decade. The main human work:
Dose-optimization / proof of concept. Polyviou/Chambers et al., Alimentary Pharmacology & Therapeutics (2016) — tested IPE variants from 0–61 wt% propionate. In vitro, IPE-27 to IPE-54 produced a sevenfold increase in propionate versus inulin; in vivo IPE-27 gave greater ¹³C recovery in breath than IPE-54, and IPE-27 reduced energy intake at an ad libitum meal versus both inulin and IPE-54. This established IPE-27 (the ~10 g dose delivering ~2.4 g propionate) as the working formulation. nih
Foundational weight/appetite trial. Chambers et al., Gut (2015; the landmark study) — acute appetite plus a 24-week study in ~60 overweight adults. Fewer IPE participants gained ≥3% body weight, and the IPE group had less abdominal and liver fat than the inulin group. This is the study most often cited for IPE’s anti-weight-gain effect.
Appetite/food-reward mechanism. Byrne et al. (2016, reported via Imperial) — an MRI study where IPE reduced neural responses to high-calorie food images and lowered intake, supporting a gut-brain appetite-signaling mechanism.
IPE in real food products. Byrne et al., Nutrients (2019) — IPE baked into bread rolls and smoothies; 21 overweight participants, crossover design, testing whether IPE keeps working when incorporated into palatable foods (rather than a plain powder) and its effect on appetite and resting energy expenditure.
Metabolic/immune mechanism. Chambers et al., Gut (2019) — a 42-day-per-arm crossover (cellulose vs inulin vs IPE, 20 g/day). Found that supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity, with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses. PubMed
The definitive weight-prevention RCT (iPREVENT). Pugh et al., eClinicalMedicine (2024), registered ISRCTN16299902 — a multi-centre, double-blind, 12-month RCT in 226 completers aged 20–40, randomized to 10 g/day IPE or inulin. The primary result was null: at 12 months there was no significant difference in baseline-adjusted mean weight gain for IPE versus control (1.02 kg, 95% CI −0.37 to 2.41; p = 0.15). This is an important, honest counterweight to the earlier positive short-term data — over a full year in younger adults, IPE did not beat plain inulin for preventing weight gain. PubMed
Body-composition / muscle signal (relevant to your longevity interest). Within that same iPREVENT trial, a secondary finding was that in the IPE arm, fat-free (lean) mass was greater by roughly 1 kg versus control — which generated coverage framing IPE as potentially favoring muscle in overweight adults. This is a secondary, hypothesis-generating outcome, not a powered primary endpoint.
Registered trials on ClinicalTrials.gov / HRA. Beyond the publications above, several registrations exist: NCT04016350 (University of Glasgow — moderate-intensity exercise plus IPE on resting fat oxidation and body weight in overweight women, completed); NCT03322514 (colonic propionate, appetite and weight loss); and a UK Health Research Authority study on propionate and bone health, which explicitly used the Glasgow-produced IPE to raise gut-derived propionate and test skeletal effects.
Mechanistic and adjacent work. The broader propionate literature — much of it citing IPE — extends into immune and airway biology (propionate acting via FFAR2/FFAR3 to dampen allergic/Th2 airway inflammation in animal models), which is why IPE recurs in reviews on gut-microbiome immunomodulation, though the direct human airway trials use inhaled fluticasone propionate (a completely unrelated compound despite the similar name — worth flagging so you don’t conflate them in searches).
Bottom line for your purposes
If you’re trying to source IPE for personal use, there is currently no clean off-the-shelf option — it’s not on Alibaba, Amazon, or the bulk nutraceutical channels, and the only sanctioned commercial route (EU novel food, live since 30 June 2026) is Imperial-exclusive and aimed at food manufacturers, not consumers. The realistic near-term paths are (1) waiting for Imperial’s spinout/licensees to bring product to market, (2) custom synthesis by a contract manufacturer using the published route (inulin + propionic anhydride), or (3) approaching plain high-DP chicory inulin plus separate propionate as an imperfect proxy — though that specifically loses the colon-targeted delivery that is IPE’s entire point.
One honest caveat on the efficacy story: the strongest human data are the short-term (weeks-to-6-months) appetite and metabolic studies, while the single largest and longest RCT (12 months) was null for its primary weight endpoint. The metabolic (insulin sensitivity) and possible lean-mass signals are more interesting than the weight-loss angle at this point.